398 related articles for article (PubMed ID: 32906840)
1. Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?
Duraisamy GS; Bhosale D; Lipenská I; Huvarova I; Růžek D; Windisch MP; Miller AD
Viruses; 2020 Sep; 12(9):. PubMed ID: 32906840
[TBL] [Abstract][Full Text] [Related]
2. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
3. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B.
Fung J; Lai CL; Yuen MF
Expert Rev Anti Infect Ther; 2010 Jun; 8(6):717-26. PubMed ID: 20521898
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
6. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
Durantel D; Zoulim F
J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
[TBL] [Abstract][Full Text] [Related]
7. [Interferon in hepatitis B].
García Buey L; González Mateos F; Moreno Otero R
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
[TBL] [Abstract][Full Text] [Related]
8. New anti-hepatitis B virus drugs under development and evaluation.
Pan J; Tong S; Kang L; Tang J
Curr Opin Infect Dis; 2016 Dec; 29(6):632-638. PubMed ID: 27783030
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus: from diagnosis to treatment.
Dény P; Zoulim F
Pathol Biol (Paris); 2010 Aug; 58(4):245-53. PubMed ID: 20580167
[TBL] [Abstract][Full Text] [Related]
10. Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus.
Cheng X; Guan W; Sun S; Li B; Li H; Kang F; Kang J; Yang D; Nassal M; Sun D
PLoS One; 2015; 10(12):e0145746. PubMed ID: 26699621
[TBL] [Abstract][Full Text] [Related]
11. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
Kao JH
Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic targets and drugs for the treatment of chronic hepatitis B.
Fletcher SP; Delaney WE
Semin Liver Dis; 2013 May; 33(2):130-7. PubMed ID: 23749669
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
[TBL] [Abstract][Full Text] [Related]
14. [Chronic hepatitis B, advances in treatment].
Buffet C
Presse Med; 2006 Feb; 35(2 Pt 2):302-3. PubMed ID: 16493333
[No Abstract] [Full Text] [Related]
15. CD3(bright)CD56(+) T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients.
Guo C; Shen X; Fu B; Liu Y; Chen Y; Ni F; Ye Y; Sun R; Li J; Tian Z; Wei H
Sci Rep; 2016 May; 6():25567. PubMed ID: 27174425
[TBL] [Abstract][Full Text] [Related]
16. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
Sayan M; Akhan SC
Int J Infect Dis; 2011 Oct; 15(10):e722-6. PubMed ID: 21784687
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B.
Fan H; Lin L; Jia S; Xie M; Luo C; Tan X; Ying R; Guan Y; Li F
J Viral Hepat; 2019 Jul; 26 Suppl 1():77-84. PubMed ID: 31380586
[TBL] [Abstract][Full Text] [Related]
18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
19. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients.
Bell SJ; Lau A; Thompson A; Watson KJ; Demediuk B; Shaw G; Chen RY; Ayres A; Yuen L; Bartholomeusz A; Locarnini SA; Desmond PV
J Clin Virol; 2005 Feb; 32(2):122-7. PubMed ID: 15653414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
